HighTower Advisors’s Rein Therapeutics RNTX Stock Holding History

HighTower Advisors’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,000	Closed	-$13K	–	4044
2026 Q1	$13K	Hold	10,000	–	–	﹤0.01%	3777
2025 Q4	$11.6K	Buy	+10,000	New	+$13.8K	﹤0.01%	3633
2023 Q4	–	Sell	-19,204	Closed	-$29K	–	3884
2023 Q3	$29K	Hold	19,204	–	–	﹤0.01%	3292
2023 Q2	$34K	Sell	19,204 -150	-0.8%	-$231	﹤0.01%	3207
2023 Q1	$24K	Buy	+19,354	New	+$41.5K	﹤0.01%	3135
2022 Q2	–	Sell	-600	Closed	-$6K	–	3595
2022 Q1	$6K	Hold	600	–	–	﹤0.01%	3261
2021 Q4	$7K	Buy	+600	New	+$9.28K	﹤0.01%	3186

Other funds holding RNTX

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

HighTower Advisors's RNTX Position: Q2 2026 in Review

HighTower Advisors sold out of Rein Therapeutics (RNTX) in Q2 2026, closing a stake of 10,000 shares — an estimated $13K sold.

HighTower Advisors first reported a position in RNTX in Q4 2021 and held it in 7 quarters. The position peaked at $34K in Q2 2023. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

HighTower Advisors reported no remaining Rein Therapeutics position as of Q2 2026 after selling out during the quarter.
HighTower Advisors sold 10,000 Rein Therapeutics shares in Q2 2026, an estimated $13K.
HighTower Advisors first reported a position in Rein Therapeutics in Q4 2021 and held it in 7 quarters.
HighTower Advisors's Rein Therapeutics position peaked at $34K in Q2 2023.
60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.